

PKC regulates the production of fibroblast growth factor 23 (FGF23)

Ludmilla Bär¹, Philipp Hase¹, Michael Föller²

¹Institute of Agricultural and Nutritional Sciences, Martin Luther University Halle-
Wittenberg, D-06120 Halle (Saale), Germany

²Institute of Physiology, University of Hohenheim, D-70599 Stuttgart, Germany

Correspondence to:

Michael Föller, MD PhD

Universität Hohenheim, Institut für Physiologie, Garbenstraße 30, D-70599 Stuttgart,
Germany

Tel: +4971145924566, Fax: +4971145923726, michael.foeller@uni-hohenheim.de

Short title: PKC and FGF23

Abstract

Serine/threonine protein kinase C (PKC) is activated by diacylglycerol that is released from membrane lipids by phospholipase C in response to activation of G protein-coupled receptors or receptor tyrosine kinases. PKC isoforms are particularly relevant for proliferation and differentiation of cells including osteoblasts. Osteoblasts/osteocytes produce fibroblast growth factor 23 (FGF23), a hormone regulating renal phosphate and vitamin D handling. PKC activates NF κ B, a transcription factor complex controlling FGF23 expression. Here, we analyzed the impact of PKC on FGF23 synthesis. *Fgf23* expression was analyzed by qRT-PCR in UMR106 osteoblast-like cells and in IDG-SW3 osteocytes. Phorbol ester 12-O-tetradecanoylphorbol-13-acetate (PMA), a PKC activator, up-regulated *Fgf23* expression. In contrast, PKC inhibitors calphostin C, Gö6976, sotrastaurin and ruboxistaurin suppressed *Fgf23* gene expression. NF κ B inhibitor withaferin A abolished the stimulatory effect of PMA on *Fgf23*. PKC is a powerful regulator of FGF23 synthesis, an effect which is at least partly mediated by NF κ B.

Introduction

Protein kinase C (PKC) isoforms are related serine/threonine kinases probably expressed in all cell types. Classically, PKC activity is induced upon stimulation of various G_q protein-coupled receptors and growth factor receptor tyrosine kinases [1]. Three classes of PKC isoforms can be distinguished: classical PKC (cPKC) isoforms are activated by both, diacylglycerol (DAG) and an increase in the intracellular Ca²⁺ concentration whereas novel PKC (nPKC) isoforms require only DAG, and atypical PKC (aPKC) isoforms are induced by other mechanism [2]. The classical activation is dependent on phospholipase C β or C γ -mediated breakdown of membrane phosphatidylinositol 4,5-bisphosphate (PIP₂) yielding inositol 1,4,5-trisphosphate (IP₃) and DAG. IP₃ binds the IP₃ receptor releasing Ca²⁺ from the endoplasmic reticulum (ER), while membrane-bound DAG activates PKC [1].

PKC is crucial for most cellular responses including the regulation of gene expression, cell migration, proliferation, differentiation, and apoptosis [3]. Moreover, PKC is implicated in the pathophysiology of frequent disorders such as heart failure, diabetes, Alzheimer and Parkinson disease, as well as inflammatory and immune disorders [3]. PKC is particularly relevant for various malignancies, owing to its tumor and metastasis-promoting properties [3]. Plant-derived phorbol esters are potent carcinogens that are effective through stimulating PKC activity [3].

Inflammation [4,5], renal and cardiovascular disease [6–8] are major triggers of the production of fibroblast growth factor 23 (FGF23), a proteohormone mainly produced in the bone [9] and implicated in the regulation of phosphate reabsorption and 1,25(OH)₂D₃ (active vitamin D [10]) formation in the kidney [11]. The FGF23-mediated inhibition of renal phosphate transporter NapiIIa and CYP27B1, the key enzyme for the generation of 1,25(OH)₂D₃, is dependent on Klotho, a transmembrane protein [9]. The induction of left ventricular hypertrophy is, however, solely mediated by FGF23 without the involvement of Klotho [8,12,13], whereas vitamin D partly overcomes the FGF23 effect on cardiac hypertrophy [14]. FGF23 also impacts on neutrophil recruitment [15], erythropoiesis [16,17], or hepatic cytokine secretion [18] in a paracrine manner.

Klotho or FGF23 deficiency results in rapid aging, a very short life span, and multiple age-associated diseases affecting most organs and tissues [11,19]. This dramatic phenotype of Klotho or FGF23 null mice is almost completely rescued by a phosphate- or vitamin D-deficient diet [20,21], pointing to the predominant role of calcification in the pathophysiology of Klotho or FGF23 deficiency [22]. Apart from its endocrine and paracrine effects that are still incompletely understood, FGF23 is a putative disease biomarker [6,23]. The plasma level of FGF23 correlates well with progression of chronic kidney disease (CKD) and is a very sensitive marker that is elevated even before onset of hyperphosphatemia or hyperparathyroidism [24,25]. Further, FGF23 levels are elevated in acute kidney injury [26,27]. Whether and to which extent FGF23 not only indicates disease but actively contributes to disease progression, as shown for the heart, remains unclear.

The identification of molecular regulators of FGF23 production is of high interest and relevance. Known regulators include PTH [28], 1,25(OH)₂D₃ [29], phosphate [30,31], inflammatory cytokines and factors such as TNF α [32], IL-1/6 [4,33–35], or NF κ B [33,36], TGF β [37], AMP-dependent protein kinase (AMPK) [38] or insulin-dependent PI3 kinase signaling [39].

The present study explored the contribution of PKC signaling to the production of FGF23 in bone cells.

Materials and Methods

Cell culture

Cell culture and experiments with UMR106 rat osteoblast-like cells were conducted as described before [39]. Briefly, cells were cultured in DMEM high-glucose medium containing 10% FBS and penicillin-streptomycin at 37°C and 5% CO₂.

IDG-SW3 bone cells were cultured as described earlier [40]. Briefly, non-differentiated cells were kept at 33°C in AlphaMEM medium (with L-glutamine and deoxyribonucleosides) containing 10% FBS, penicillin-streptomycin and interferon-gamma (INF- γ ; 50 U/ml). For differentiation, cells were plated on collagen-coated dishes at 37°C in medium with 50 μ g/ml ascorbic acid and 4 mM β -glycerophosphate but without INF- γ . All reagents were from ThermoFisher unless indicated.

IDG-SW3 osteocytes were used after 35 days of differentiation, and UMR106 cells were pretreated with 100 nM 1,25(OH) $_2$ D $_3$ (Tocris, Wiesbaden-Nordenstadt, Germany) for 24h before the experiment. Cells were then incubated with activator Phorbol ester 12-O-tetradecanoylphorbol-13-acetate (PMA; Sigma, Schnelldorf, Germany; 0.1 μ M; 6 h) with or without 1 μ M PKC inhibitors Calphostin C (Tocris), Gö6976 (Tocris), sotrastaurin (Selleckchem, München, Germany), ruboxistaurin (Selleckchem), or NF κ B inhibitor withaferin A (Tocris; 0.5 μ M), or with vehicle only for another 24 h.

Expression analysis

Total RNA was extracted using peqGOLD TriFast reagent (VWR, Dresden, Germany). Complementary DNA (cDNA) was synthesized from 1.2 μ g RNA using random primers and the GoScriptTM Reverse Transcription System (Promega, Mannheim, Germany) at 25°C for 5 min, 42°C for 1 h, and 70°C for 15 min.

The expression profile of PKC isoforms in UMR106 cells was studied by RT-PCR using the GoTaq Green Master Mix (Promega) and the primers listed in Table 1. For the PCR, 2 μ l synthesized cDNA were used. Settings were: 95°C for 3 min, followed by 35 cycles of 95°C for 30 s, 60°C for 30s, 72°C for 45s. PCR products were loaded on a 1.5% agarose-gel and visualized by Midori Green (Biozym, Hessisch

Oldendorf, Germany), and a 100 bp DNA ladder (Jena Bioscience, Jena, Germany) was used as a size marker.

Table 1: Primer sequences.

name	sequence (5'-3')	product
<i>PKCα_forward</i>	CTGAACCCTCAGTGGAAATGAGT	326 bp
<i>PKCα_reverse</i>	GGCTGCTTCCTGTCTTCTGAA	
<i>PKCβ_forward</i>	AACGGCTTGTCAGATCCCTA	250 bp
<i>PKCβ_reverse</i>	CCACTCCGGCTTCTGTAGT	
<i>PKCγ_forward</i>	AGTCCCACGGACTCCAAGAG	397 bp
<i>PKCγ_reverse</i>	CGGCATAGAATGCTGCGTG	
<i>PKCδ_forward</i>	TGTGAAGACTGCGGCATGAA	265 bp
<i>PKCδ_reverse</i>	AGGTGAAGTTCTCAAGGCGG	
<i>PKCϵ_forward</i>	CGAGGACGACTTGTTTGAATCC	389 bp
<i>PKCϵ_reverse</i>	CAGTTTCTCAGGGCATCAGGTC	
<i>PKCζ_forward</i>	GTGGACCCCACGACAACCTT	207 bp
<i>PKCζ_reverse</i>	GATGCTTGGGAAAACGTGGA	
<i>PKCη_forward</i>	CCATGAAGATGCCACAGGGATC	249 bp
<i>PKCη_reverse</i>	TCATCGATCGGAGTTAAAACAGG	
<i>PKCθ_forward</i>	TGCCGACAATGTAATGCAGC	219 bp
<i>PKCθ_reverse</i>	ACACTTGAGACCTTGCCTCG	
<i>PKCι_forward</i>	CTCCTGATCCACGTGTTCCC	321 bp
<i>PKCι_reverse</i>	GGATGACTGGTCCATTGGCA	

qRT-PCR

Relative expression levels of *Fgf23* were determined by qRT-PCR using 2 μ l synthesized cDNA and the GoTaq qPCR Master Mix (Promega) on a Rotor-Gene Q (Qiagen, Hilden, Germany). PCR conditions were 95°C for 3 min, followed by 35 cycles of 95°C for 10 s, 58°C for 30 s and 72°C for 45 s. After normalization to *Tbp*

(TATA box-binding protein) expression, relative quantification of gene expression based on the double-delta Ct (threshold cycle) analysis was carried out.

Primers used:

Tbp

F: ACTCCTGCCACACCAGCC

R: GGTCAAGTTTACAGCCAAGATTCA

Fgf23

F: TGGCCATGTAGACGGAACAC

R: GGCCCCTATTATCACTACGGAG

Statistics

Arithmetic means \pm SEM were calculated, and *n* represents the number of independent experiments. Comparisons of two groups were made by unpaired Student's *t* test, and for more than two groups, comparisons were calculated via one-way ANOVA, followed by Tukey's or Dunnett's multiple comparison tests, using GraphPad Prism. Differences were considered significant if $p < 0.05$.

Results

The relevance of PKC activity for the synthesis of FGF23 was studied in UMR106 osteoblast-like cells and IDG-SW3 osteocytes. First, the expression of PKC isoforms was explored by RT-PCR. As demonstrated in Fig 1, mRNA specific for PKC α , PKC δ , PKC ϵ , PKC η , PKC θ , and PKC ι could readily be detected. The bands indicating the abundance of PKC β , PKC γ , PKC ζ mRNA in UMR106 cells were weaker albeit detectable.

Fig 1: Expression of PKC isoforms in UMR106 osteoblast-like cells.

Original agarose gel photo showing PKC α , - β , - γ , - δ , - ϵ , - ζ , - η , - θ or - ι specific cDNA in UMR106 cells. NC: non-template control

Phorbol ester 12-O-tetradecanoylphorbol-13-acetate (PMA) is a potent activator of PKC [3]. We treated UMR106 cells with and without PMA and determined *Fgf23* transcripts by qRT-PCR. PMA treatment significantly up-regulated the abundance of *Fgf23* mRNA (Fig 2A). Similar to osteoblasts, PKC activation with PMA enhanced *Fgf23* gene expression in IDG-SW3 osteocytes (Fig 2B). These results suggest that PKC activity drives *Fgf23* gene expression in osteoblasts and osteocytes.

Fig 2: PKC activator PMA induces *Fgf23* gene expression in UMR106 osteoblast-like cells and in IDG-SW3 osteocytes.

Arithmetic means \pm SEM (n=6) of relative *Fgf23* mRNA abundance normalized to *Tbp* in UMR106 osteoblast-like cells (A) or IDG-SW3 osteocytes (B) incubated without (white bars) or with (black bars) 0.1 μ M PKC activator PMA. * $p < 0.05$ indicates significant difference. arb., arbitrary

Our next series of experiments tested whether inhibition of PKC interferes with *Fgf23* gene expression. To this end, UMR106 cells were exposed to PKC inhibitors. As demonstrated in Fig 3, PKC inhibitor calphostin C (Fig 3A) and also PKC α/β inhibitor Gö6976 (Fig 3B) significantly and dose-dependently down-regulated *Fgf23* gene expression in UMR106 cells. Thus, PKC is a stimulator of *Fgf23* gene expression.

Fig 3: PKC inhibitors Calphostin C and Gö6976 decrease *Fgf23* transcript levels in UMR106 osteoblast cells.

The bar diagrams represent the relative mRNA abundance of *Fgf23* in UMR106 cells incubated without or with PKC inhibitors Calphostin C (A) or Gö6976 (B) at the indicated concentrations. Gene expression was normalized to *Tbp* as a housekeeping gene, and the values are expressed as arithmetic means \pm SEM (n = 6). * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ indicate significant difference.

Furthermore, we investigated whether PMA-stimulated *Fgf23* gene expression is indeed dependent on PKC activity using UMR106 and IDG-SW3 cells. As demonstrated in Fig 4, the PMA effect on *Fgf23* gene expression was completely abrogated by PKC inhibitor Gö6976 in UMR106 osteoblast-like cells (Fig 4A) and in IDG-SWR3 osteocytes (Fig 4B), and also by PKC inhibitors sotrastaurin (Fig 4C) and ruboxistaurin (Fig 4D) in UMR106 cells.

Fig 4: PKC inhibition abrogates the PMA-induced increase in *Fgf23* gene expression in UMR106 osteoblast-like cells and in IDG-SW3 osteocytes.

Relative *Fgf23* transcript levels in UMR106 cells (A,C,D) or in IDG-SW3 cells (B) incubated without or with PMA (0.1 μ M, A-D) in the absence and presence of PKC α/β inhibitor Gö6976 (1 μ M, A,B), pan PKC inhibitor Sotrastaurin (1 μ M, C) or PKC β inhibitor Ruboxistaurin (1 μ M, D). Gene expression was normalized to *Tbp* as a housekeeping gene, and the values are expressed as arithmetic means \pm SEM (n = 6). * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate significant difference from vehicle (first bar). #### p < 0.001 indicates significant difference from the absence of PKC inhibitor (second bar vs. fourth bar). arb., arbitrary.

Finally, we sought to identify the mechanism of PKC-dependent FGF23 regulation. Since PKC is an activator of NF κ B [41], a known regulator of FGF23, we treated UMR106 cells with and without NF κ B inhibitor withaferin A in the absence and presence of PMA and determined *Fgf23* gene expression. As demonstrated in Fig 5, the PMA effect was indeed abrogated by withaferin A. Hence, PKC was, at least in part, effective through NF κ B activity.

Fig 5: The PKC effect on *Fgf23* gene expression is dependent on NF κ B.

Relative *Fgf23* transcript levels in UMR106 cells incubated without or with PMA (0.1 μ M) in the absence and presence of NF κ B inhibitor Withaferin A (0.5 μ M). Gene expression was normalized to *Tbp* as a housekeeping gene, and the values are expressed as arithmetic means \pm SEM (n = 6). ** p < 0.01, and *** p < 0.001 indicate significant difference from vehicle (first bar). #### p < 0.001 indicates significant difference from the absence of withaferin A (second bar vs. fourth bar). arb., arbitrary.

Discussion

Our study discloses PKC as a novel regulator of FGF23 production. We provide experimental evidence that activation of PKC induces and inhibition of PKC suppresses *Fgf23* gene expression: Four different PKC inhibitors were similarly capable of completely blocking PMA-induced *Fgf23* expression. This result unequivocally demonstrates the powerful role of PKC in regulating FGF23 production.

FGF23 is mainly produced by osteoblasts/osteocytes in the bone [9]. The differentiation of osteoblasts is driven by transcription factor MSX2 [42]. PKC enhances the proliferation of osteoblasts [43]. In contrast, PKC inhibits the differentiation of osteoblasts by targeting MSX2 [44] whereas FGF23 induces MSX2. [45]. Transcriptional activity of Runx2, also implicated in osteoblast differentiation, is enhanced by both PKC [46] and FGF23 [47].

We could show that four different pharmacological PKC inhibitors potently suppressed *Fgf23* gene expression. PKC inhibition has been suggested as a therapeutic approach in multiple diseases including cancer, sequelae of diabetes, cardiovascular diseases, or inflammatory disorders such as psoriasis [48]. Particularly renal and cardiovascular diseases are associated with elevated FGF23 plasma levels [6], and FGF23 not only indicates disease, but actively contributes at least to left heart hypertrophy [12,13]. Therefore, the therapeutic benefit of PKC inhibitors may at least in part also be due to their FGF23-lowering capacity.

Two different cell lines representing both osteoblasts and mature osteocytes were used in our study to decipher the effect of PKC on FGF23: PKC activation with PMA enhanced and PKC inhibition with different PKC inhibitors suppressed *Fgf23* gene expression in both UMR106 osteoblast-like cells and IDG-SW3 osteocytes. This result suggests PKC-dependent regulation of FGF23 formation as a universal mechanism for the control of this hormone.

In an attempt to identify the underlying mechanism we found that PKC-mediated up-regulation of *Fgf23* expression is sensitive to NF κ B inhibition. NF κ B, as a p65/p50 dimer, is inactivated by binding inhibitory κ B (I κ B). The inhibitory κ B kinase (IKK) phosphorylate I κ B, leading to its ubiquitination and degradation, paralleled by the release and activation of NF κ B [49]. Therefore, the activation of the IKK complex plays a crucial role in the induction of NF κ B, and PKC activates NF κ B through this kinase [41]. Clearly, inflammation is a major trigger of FGF23 production [4,36]. In detail, NF κ B up-regulates Ca²⁺ release-activated Ca²⁺ (CRAC) channel Orai1/STIM1 accomplishing store-operated Ca²⁺ entry (SOCE) and inducing the transcription of the *Fgf23* gene [36]. According to our experiment with NF κ B inhibitor withaferin A, the PKC effect on FGF23 was, at least partly, dependent on NF κ B pointing to the decisive role of this pro-inflammatory transcription factor complex in the regulation of FGF23.

In conclusion, our study identified PKC as a novel regulator of FGF23 production in both osteoblast and osteocytes, being at least partially effective via the NF κ B signaling pathway.

Therefore, the therapeutic modulation of PKC activity in chronic disease may impact on the plasma FGF23 concentration.

Acknowledgements

The authors acknowledge the technical assistance of S. Ross and F. Reipsch.

Author contributions

Conceptualization: Michael Föller.

Formal analysis: Ludmilla Bär.

Funding acquisition: Michael Föller.

Investigation: Ludmilla Bär, Philipp Hase.

Supervision: Michael Föller.

Writing: Ludmilla Bär, Michael Föller.

Funding

The study was supported by the Deutsche Forschungsgemeinschaft [Fo 695/2-1].

Conflict of interest

None declared.

References

1. STEINBERG SF. Structural basis of protein kinase C isoform function. *Physiol Rev.* 2008; 88: 1341–1378. doi: 10.1152/physrev.00034.2007.
2. Mackay HJ, Twelves CJ. Targeting the protein kinase C family: are we there yet. *Nat Rev Cancer.* 2007; 7: 554–562. doi: 10.1038/nrc2168.
3. Isakov N. Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. *Semin Cancer Biol.* 2018; 48: 36–52. doi: 10.1016/j.semcancer.2017.04.012.
4. David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. *Kidney Int.* 2016; 89: 135–146. doi: 10.1038/ki.2015.290.
5. Hanks LJ, Casazza K, Judd SE, Jenny NS, Gutiérrez OM. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. *PLoS ONE.* 2015; 10: e0122885. doi: 10.1371/journal.pone.0122885.
6. Schnedl C, Fahrleitner-Pammer A, Pietschmann P, Amrein K. FGF23 in Acute and Chronic Illness. *Dis Markers.* 2015; 2015: 358086. doi: 10.1155/2015/358086.
7. Spichtig D, Zhang H, Mohebbi N, Pavik I, Petzold K, Stange G, et al. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. *Kidney Int.* 2014; 85: 1340–1350. doi: 10.1038/ki.2013.526.
8. Itoh N, Ohta H. Pathophysiological roles of FGF signaling in the heart. *Front Physiol.* 2013; 4: 247. doi: 10.3389/fphys.2013.00247.
9. Kuro-O M, Moe OW. FGF23- α Klotho as a paradigm for a kidney-bone network. *Bone.* 2017; 100: 4–18. doi: 10.1016/j.bone.2016.11.013.
10. Tsuprykov O, Chen X, Hoche C-F, Skoblo R, Lianghong Y, Hoche B. Why should we measure free 25(OH) vitamin D. *J Steroid Biochem Mol Biol.* 2018; 180: 87–104. doi: 10.1016/j.jsbmb.2017.11.014.
11. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of *Fgf23* demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. *J Clin Invest.* 2004; 113: 561–568. doi: 10.1172/JCI19081.
12. Faul C, Amaral AP, Oskouei B, Hu M-C, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. *J Clin Invest.* 2011; 121: 4393–4408. doi: 10.1172/JCI46122.
13. Faul C. Cardiac actions of fibroblast growth factor 23. *Bone.* 2017; 100: 69–79. doi: 10.1016/j.bone.2016.10.001.
14. Leifheit-Nestler M, Grabner A, Hermann L, Richter B, Schmitz K, Fischer D-C, et al. Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats. *Nephrol Dial Transplant.* 2017; 32: 1493–1503. doi: 10.1093/ndt/gfw454.
15. Rossaint J, Oehmichen J, van Aken H, Reuter S, Pavenstädt HJ, Meersch M, et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. *J Clin Invest.* 2016; 126: 962–974. doi: 10.1172/JCI83470.
16. Agoro R, Montagna A, Goetz R, Aligbe O, Singh G, Coe LM, et al. Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. *FASEB J.* 2018; 32: 3752–3764. doi: 10.1096/fj.201700667R.
17. Flamme I, Ellinghaus P, Urrego D, Krüger T. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase. *PLoS ONE.* 2017; 12: e0186979. doi: 10.1371/journal.pone.0186979.
18. Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. *Kidney Int.* 2016; 90: 985–996. doi: 10.1016/j.kint.2016.05.019.
19. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse *klotho* gene leads to a syndrome resembling ageing. *Nature.* 1997; 390: 45–51. doi: 10.1038/36285.
20. Kuro-O M. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. *Nat Rev Nephrol.* 2013; 9: 650–660. doi: 10.1038/nrneph.2013.111.
21. Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. *J Am Soc Nephrol.* 2007; 18: 2116–2124. doi: 10.1681/ASN.2006121385.
22. Voelkl J, Alesutan I, Leibrock CB, Quintanilla-Martinez L, Kuhn V, Feger M, et al. Spironolactone ameliorates P1T1-dependent vascular osteoinduction in *klotho*-hypomorphic mice. *J Clin Invest.* 2013; 123: 812–822. doi: 10.1172/JCI64093.
23. Kuro-O M. Klotho and endocrine fibroblast growth factors: marker of chronic kidney disease progression and cardiovascular complications. *Nephrol Dial Transplant.* 2018. doi: 10.1093/ndt/gfy126.

24. Gracioli FG, Neves KR, Barreto F, Barreto DV, Dos Reis LM, Canziani ME, et al. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. *Kidney Int.* 2017; 91: 1436–1446. doi: 10.1016/j.kint.2016.12.029.
25. Pulskens WP, Verkaik M, Sheedfar F, van Loon EP, van de Sluis B, Vervloet MG, et al. Deregulated Renal Calcium and Phosphate Transport during Experimental Kidney Failure. *PLoS ONE.* 2015; 10: e0142510. doi: 10.1371/journal.pone.0142510.
26. Egli-Spichtig D, Zhang MYH, Perwad F. Fibroblast Growth Factor 23 Expression Is Increased in Multiple Organs in Mice With Folic Acid-Induced Acute Kidney Injury. *Front Physiol.* 2018; 9: 1494. doi: 10.3389/fphys.2018.01494.
27. Christov M. Fibroblast growth factor 23 in acute kidney injury. *Curr Opin Nephrol Hypertens.* 2014; 23: 340–345. doi: 10.1097/01.mnh.0000447021.51722.2f.
28. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. *Am J Physiol Renal Physiol.* 2010; 299: F882-9. doi: 10.1152/ajprenal.00360.2010.
29. Masuyama R, Stockmans I, Torrekens S, van Looveren R, Maes C, Carmeliet P, et al. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. *J Clin Invest.* 2006; 116: 3150–3159. doi: 10.1172/JCI29463.
30. Ferrari SL, Bonjour J-P, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. *J Clin Endocrinol Metab.* 2005; 90: 1519–1524. doi: 10.1210/jc.2004-1039.
31. Rodelo-Haad C, Rodríguez-Ortiz ME, Martín-Malo A, Pendón-Ruiz de Mier MV, Agüera ML, Muñoz-Castañeda JR, et al. Phosphate control in reducing FGF23 levels in hemodialysis patients. *PLoS ONE.* 2018; 13: e0201537. doi: 10.1371/journal.pone.0201537.
32. Glosse P, Fajol A, Hirche F, Feger M, Voelkl J, Lang F, et al. A high-fat diet stimulates fibroblast growth factor 23 formation in mice through TNF α upregulation. *Nutr Diabetes.* 2018; 8: 36. doi: 10.1038/s41387-018-0037-x.
33. Ito N, Wijenayaka AR, Prideaux M, Kogawa M, Ormsby RT, Evdokiou A, et al. Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. *Mol Cell Endocrinol.* 2015; 399: 208–218. doi: 10.1016/j.mce.2014.10.007.
34. Yamazaki M, Kawai M, Miyagawa K, Ohata Y, Tachikawa K, Kinoshita S, et al. Interleukin-1-induced acute bone resorption facilitates the secretion of fibroblast growth factor 23 into the circulation. *J Bone Miner Metab.* 2015; 33: 342–354. doi: 10.1007/s00774-014-0598-2.
35. Durlacher-Betzer K, Hassan A, Levi R, Axelrod J, Silver J, Naveh-Many T. Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease. *Kidney Int.* 2018; 94: 315–325. doi: 10.1016/j.kint.2018.02.026.
36. Zhang B, Yan J, Umbach AT, Fakhri H, Fajol A, Schmidt S, et al. NF κ B-sensitive Orai1 expression in the regulation of FGF23 release. *J Mol Med.* 2016; 94: 557–566. doi: 10.1007/s00109-015-1370-3.
37. Feger M, Hase P, Zhang B, Hirche F, Glosse P, Lang F, et al. The production of fibroblast growth factor 23 is controlled by TGF- β 2. *Sci Rep.* 2017; 7: 4982. doi: 10.1038/s41598-017-05226-y.
38. Glosse P, Feger M, Mutig K, Chen H, Hirche F, Hasan AA, et al. AMP-activated kinase is a regulator of fibroblast growth factor 23 production. *Kidney Int.* 2018; 94: 491–501. doi: 10.1016/j.kint.2018.03.006.
39. Bär L, Feger M, Fajol A, Klotz L-O, Zeng S, Lang F, et al. Insulin suppresses the production of fibroblast growth factor 23 (FGF23). *Proc Natl Acad Sci U S A.* 2018; 115: 5804–5809. doi: 10.1073/pnas.1800160115.
40. Woo SM, Rosser J, Dusevich V, Kalajzic I, Bonewald LF. Cell line IDG-SW3 replicates osteoblast-to-late-osteocyte differentiation in vitro and accelerates bone formation in vivo. *J Bone Miner Res.* 2011; 26: 2634–2646. doi: 10.1002/jbmr.465.
41. Moscat J, Diaz-Meco MT, Rennert P. NF-kappaB activation by protein kinase C isoforms and B-cell function. *EMBO Rep.* 2003; 4: 31–36. doi: 10.1038/sj.embor.embor704.
42. Ichida F, Nishimura R, Hata K, Matsubara T, Ikeda F, Hisada K, et al. Reciprocal roles of MSX2 in regulation of osteoblast and adipocyte differentiation. *J Biol Chem.* 2004; 279: 34015–34022. doi: 10.1074/jbc.M403621200.
43. Galea GL, Meakin LB, Williams CM, Hulin-Curtis SL, Lanyon LE, Poole AW, et al. Protein kinase C α (PKC α) regulates bone architecture and osteoblast activity. *J Biol Chem.* 2014; 289: 25509–25522. doi: 10.1074/jbc.M114.580365.
44. Jeong HM, Jin Y-H, Choi YH, Yum J, Choi J-K, Yeo C-Y, et al. PKC signaling inhibits osteogenic differentiation through the regulation of Msx2 function. *Biochim Biophys Acta.* 2012; 1823: 1225–1232. doi: 10.1016/j.bbamcr.2012.05.018.
45. Jimbo R, Kawakami-Mori F, Mu S, Hirohama D, Majtan B, Shimizu Y, et al. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. *Kidney Int.* 2014; 85: 1103–1111. doi: 10.1038/ki.2013.332.

46. Kim H-J, Kim J-H, Bae S-C, Choi J-Y, Ryoo H-M. The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. *J Biol Chem.* 2003; 278: 319–326. doi: 10.1074/jbc.M203750200.
47. Orfanidou T, Iliopoulos D, Malizos KN, Tsezou A. Involvement of SOX-9 and FGF-23 in RUNX-2 regulation in osteoarthritic chondrocytes. *J Cell Mol Med.* 2010; 13: 3186–3194. doi: 10.1111/j.1582-4934.2009.00678.x.
48. Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target. *Nat Rev Drug Discov.* 2012; 11: 937–957. doi: 10.1038/nrd3871.
49. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. *Nat Rev Mol Cell Biol.* 2007; 8: 49–62. doi: 10.1038/nrm2083.




Figure 1



A**B**

Figure 2



A**B**

Figure 3








Figure 4

relative *Fgf23* expression

[arb. units]

1.5
1.0
0.5
0.0



Withaferin A

Figure 5